At Abington Neurological Associates, we see firsthand how our patients are affected by unfair insurance denials for new Alzheimer’s treatments like Leqembi. In a new article in Being Patient, Dr. Weisman and our staff discuss these hurdles and the ongoing fight to overturn unjust decisions.
It’s the first time in my 28-year career I’ve seen an anonymous insurance denial.